We are looking for advanced delivery technologies in the following focus areas:

Disease Focus Areas

• Immunology

• Inflammatory Disease

(Both areas share the same technology interests.)

Technology Interests

• Tissue/Cell-Selective Delivery Systems: Platforms that achieve targeted accumulation at specific immune or inflammatory sites, reducing off-target effects and enhancing therapeutic efficiency.

• Lipid- or Polymer-Based Nanoparticle Systems:

o     Lipid nanoparticles (LNPs) designed for mRNA, peptide, or small molecule encapsulation.

o     Biodegradable polymer-based nanoparticles with tunable release and targeting profiles.

o     Systems capable of sustained release or environmentally responsive delivery.

Required Stage:

• In vivo efficacy data required.

Problem Statement

While the therapeutic landscape in immunology and inflammation has expanded, current treatments often struggle with systemic side effects and poor localization. There is a critical need for next-generation delivery platforms that offer targeted, controlled, and biocompatible solutions to improve the safety and effectiveness of immuno-therapeutics. Celltrion is looking to fill this gap through partnerships with innovators in drug delivery science.

Why Apply?

This is a compelling opportunity to collaborate with Celltrion, a biopharmaceutical leader who developed the first biosimilar with deep expertise in drug development and biologics manufacturing. Celltrion is open to worldwide partnerships beyond the APAC region, offering selected innovators access to co-development, investment, licensing, and commercialisation opportunities. Join us in shaping the next wave of targeted drug delivery platforms that can transform lives and redefine care standards.

Submissions close on 30 June

Apply now and shape the next frontier in targeted therapeutic delivery.

For inquiries, please contact startup.relations@ventureblick.com

创新具体要求

我们正在寻找以下重点领域的先进递送技术：

重点疾病领域

• 肿瘤

• 代谢性疾病

（不同的应用领域，相同的技术方向）

技术方向

• 作用于组织/细胞的递送系统：能实现药物在特定病灶部位的靶向聚集，减少脱靶效应并提高免疫和炎症治疗效率。

• 脂质纳米颗粒系统或聚合物纳米颗粒系统：

o     用于装运 mRNA、肽或小分子的脂质纳米颗粒 (LNP)。

o     具有可控释放和靶向特性的可生物降解的聚合物纳米颗粒。

o     缓释型或环境响应型递送系统。

当前挑战

尽管免疫疾病和炎症的治疗前景不断拓展，但目前的治疗方法往往存在全身性副作用和靶向性差的问题。我们迫切期待为新一代的递送平台找到显著增强靶向性、可控度和生物相容性的解决方案，从而提高免疫疗法的安全性和有效性。Celltrion 希望通过药物递送科学领域的创新合作来填补这一空白。

为何申请？

这是与领先的生物制药跨国公司 Celltrion 合作的一个绝佳机会。Celltrion 是世界上首个单克隆抗体生物类似药的开发者，拥有药物开发和生物制剂生产的深厚能力。Celltrion 积极在亚太地区乃至全球探索合作，将为其选择的创新伙伴提供共同开发、投资、许可和商业化的多种潜在机会。与我们携手，塑造下一代靶向药物递送系统，刷新护理标准并点亮生命希望。

申请提交截止日：6 月 30 日

立即申请，拓展靶向治疗领域的技术前沿。

如需咨询更多信息，请发送邮件至 startup.relations@ventureblick.com